Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-Associated chronic anterior uveitis: Long-term results

British Journal of Ophthalmology

Volumn 98, Issue 4, 2014, Pages 523-528

  Doycheva, Deshka ^a,b   Zierhut, Manfred ^a   Blumenstock, Gunnar ^c   Stuebiger, Nicole ^a   Januschowski, Kai ^d   Voykov, Bogomil ^a   Deuter, Christoph ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Knappschaft Eye Hospital   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTINUCLEAR ANTIBODY; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE ACETATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; EYE DROPS; GLUCOCORTICOID; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ABSENCE OF SIDE EFFECTS; ANAPHYLACTOID PURPURA; ARTICLE; CATARACT; CATARACT EXTRACTION; CHICKENPOX; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; COMMON COLD; DISEASE COURSE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EYE SYNECHIA; FEMALE; GINGIVITIS; GLAUCOMA; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; INTRAOCULAR HYPOTENSION; IRIDOCYCLITIS; KERATOPATHY; MALE; PRIORITY JOURNAL; RASH; RELAPSE; RETINA MACULA EDEMA; RETROSPECTIVE STUDY; SCARLET FEVER; TREATMENT DURATION; UVEITIS; VISUAL ACUITY; ADOLESCENT; ANTAGONISTS AND INHIBITORS; ANTERIOR EYE CHAMBER; BLOOD; IMMUNOLOGY; IMMUNOMODULATION; INFANT; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; UVEITIS, ANTERIOR;

ADOLESCENT; ANTERIOR CHAMBER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; IMMUNOMODULATION; INFANT; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; MALE; OPHTHALMIC SOLUTIONS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS, ANTERIOR; VISUAL ACUITY;

EID: 84896548525     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303935     Document Type: Article

References (25)

1. Foster CS. Diagnosis and treatment of juvenile idiopathic-Associated uveitis. Curr Opin Ophthalmol 2003;14:395-8.
2. Heinz C, Mingels A, Goebel C, et al. Chronic uveitis in children with and without juvenile idiopathic arthritis: differences in patients characteristics and clinical course. J Rheumatol 2008;35:1403-7.
3. Heiligenhaus A, Niewerth M, Ganser G, et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology 2007;46:1015-19.
4. Saurenmann RK, Levin AV, Feldmann BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term follow-up study. Arthritis Rheum 2007;56:647-57.
5. Saurenmann RK, Levin AV, Rose JB, et al. Tumor necrosis factor α inhibitors in the treatment of childhood uveitis. Rheumatology 2006;45:982-9.
6. Tynjälä P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with reftactory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-50.
7. Foeldvari I, Nielsen S, Kmmerle-Deschner J, et al. Tumor necrosis factor-α blocker in treatment of juvenile idiopathic arthritis-Associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007;34:1146-50.
8. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-24.
9. Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol 2007;144:844-9.
10. Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 2011;63:612-18.
11. Kotaniemi K, Säilä H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 2011;5:1425-9.
12. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16.
13. Heiligenhaus A, Foeldvari I, Edelsten C, et al. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-Associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res 2012;64:1365-72.
14. Lerman MA, Burnham JM, Chang PY, et al. Response of pediatric uveitis to tumor necrosis factor-α inhibitors. J Rheumatol 2013;40:1394-403.
15. De Vos AF, Van Haren MA, Verhagen C, et al. Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat. Exp Eye Res 1995;61:667-75.
16. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252-7.
17. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol 2003;87:925.
18. Simonini G, Zannin ME, Caputo R, et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology 2008;47:1510-14.
19. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-Analysis. Ann Rheum Dis 2012;72:1947-55.
20. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.
21. de Vries MK, Wolbink GJ, Stapel SO, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007;66:1252-4.
22. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn?s disease. N Engl J Med 2003;348:601-8.
23. Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye 2009;23:1868-70.
24. Thorne JE, Woreta FA, Dunn JP, et al. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 2010;117:1436-41.
25. Thorne JE, Woreta F, Kedhar SR, et al. Juvenile idiopathic arthritis-Associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol 2007;143:840-6.